Supprelin LA.
Published date: 2020-12-18 22:54:27
|
Name | Histrelin | CAS# | 76712-82-8 |
|---|---|---|---|---|
| Price | $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg | Purity | 98.0% | |
| Stocking Period |
3 Day | Stock | 3 | |
| Product Webpage: | https://www.dcchemicals.com/product_show-Supprelin_LA.html | |||
| Detail
Product Information
Histrelin acetate is a nonapeptide analog of gonadotropin-releasing hormone (GnRH) with added potency. When present in the bloodstream, it acts on particular cells of the pituitary gland called gonadotropes. Histrelin stimulates these cells to release luteinizing hormone and follicle-stimulating hormone. Thus it is considered a gonadotropin-releasing hormone agonist or GnRH agonist. Histrelin is marketed by Endo Pharmaceuticals under the brand names Vantas and Supprelin LA. Histrelin is used to treat hormone-sensitive cancers of the prostate in men and uterine fibroids in women. In addition, histrelin has been proven to be highly effective in treating central precocious puberty in children. It is available as a daily intramuscular injection. Histrelin is also available in a 12-month subcutaneous implant (Vantas) for the palliative treatment of advanced prostate cancer (since 2005 in the US, and since Jan 2010 in the UK. A 12-month subcutaneous implant (Supprelin LA) for central precocious puberty (CPP) was approved on May 3, 2007 by the U.S. Food and Drug Administration. (See http://en.wikipedia.org/wiki/Histrelin.) |
DC Chemicals Limited
Chemsrc Level: Verified
Product #: 34963
Tel: 58447131
Address: Jinyu Rd100, pudong
Area: China
Contact: Tony Cao
Contact Phone #: 13564518121
Email: sales@dcchemicals.com
Website: http://www.dcchemicals.com
Major Market:
Foreign Trade % of Sales:
Major partners: